Abstract
A gas chromatographic/mass spectrometric procedure using single-ion monitoring and repetitive scanning was developed to characterize and determine methyl methanesulphonate (MMS) and ethyl methanesulphonate (EMS) in the free base and bismesylate salt of DPI 201-106, a positive inotropic agent used in the treatment of heart failure. Mass spectral fragmentations, leading to product ions, are rationalized and mechanisms of potential rearrangement pathways are described. The apparent levels of MMS and EMS, as measured against the internal standard n-propyl methanesulphonate, were found to be 0.51 and 1.31 micrograms per gram of bismesylate salt, respectively. The presence of these alkylating agents in the free base was not observed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
